Expert Ratings For Relay Therapeutics
Portfolio Pulse from Benzinga Insights
Relay Therapeutics (NASDAQ:RLAY) has been analyzed by 5 analysts, showing a range of sentiments from bullish to somewhat bullish. The average 12-month price target has decreased by 8.93% to $20.4. Analysts have adjusted their ratings and price targets, reflecting dynamic market conditions and company performance. Despite significant revenue growth, the company faces challenges with ROE and ROA below industry standards.
July 17, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Relay Therapeutics has received mixed analyst ratings, with a decrease in the average 12-month price target to $20.4. The company shows strong revenue growth but faces challenges with ROE and ROA below industry standards.
The mixed analyst ratings and the decrease in the average price target suggest a neutral short-term impact on the stock price. While the company shows strong revenue growth, the challenges with ROE and ROA may offset positive sentiments.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100